This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
-
Merck: La administración de Vioxx (F)
Simons, Robert L.; Kindred, NatalieCase HBS-111S07Knowledge and CommunicationStarting at €5.74
-
Creatividad e innovación. Cómo fomentarlas
Wilkinson, Helen; Cardona Soriano, PabloTechnical Note DPON-54Leadership and People ManagementEsta nota técnica tiene como objetivo ayudar al desarrollo personal de la competencia directiva de creatividad. Una empresa no es creativa e innovadora de por sí, como ente abstracto. Si lo es, es porque las personas que la integran son creativas. Ahora bien, el talento creativo ¿es sólo propiedad de unos pocos privilegiados o cualquier ser humano puede desarrollarlo? El talento se compone de actitud y aptitud, es decir, de predisposición y capac...Starting at €8.20
-
Merck: Managing Vioxx (E)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-109084-EStarting at €5.74
-
El propósito de Makonsa (E)
Almandoz, John; Cardona Soriano, Pablo; Chinchilla, Nuria; Rey, CarlosCase DPO-772Leadership and People ManagementEste ejercicio sirve para aprender a utilizar la dirección por objetivos y misiones como metodología de implantación de la misión en la empresa. Los participantes se dividen en cuatro equipos, que representan cuatro departamentos básicos de la empresa. Cada equipo tiene que desarrollar las misiones participadas, los indicadores y los objetivos para contribuir a la misión de la empresa. Este caso está basado en "La misión de Makonsa (B)" , DPO-429...Starting at €5.74
-
Merck: La administración de Vioxx (E)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-111S06Knowledge and CommunicationStarting at €5.74
-
Managing Vioxx (A) (Spanish version)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-111S02Strategy(B) evidence of life-threatening side effects, (C) decision options, (D) announcement to withdraw Vioxx, (E) reaction by patients, shareholders, media, and regulators, (F) Merck fights back, and (G) wrap-up. At the end of the case series, students may conclude that doing the right thing sometimes requires very hard choices.Starting at €8.20
-
Shanghai Pharmaceuticals
Herzlinger, Regina E.; Kindred, NatalieCase HBS-313016-EStrategyShanghai Pharmaceuticals (SPH), a vertically integrated Chinese pharmaceutical conglomerate, was considering its strategic options in the context of a rapidly evolving industry, policy, and economic environment. The company-essentially a collection of subsidiaries operating under a unified management structure-was formed through the 2009 merger of several state-owned enterprises, part of a broad policy effort in China to streamline state assets, ...Starting at €8.20
-
McKesson
Herzlinger, Regina E.; Kindred, NatalieCase HBS-312002-EMcKesson, a large, diversified drug distribution and health care IT company, is considering development of new business offerings to help private practice physicians remain independent. The company, with $122 billion in 2010 revenues, just made its first foray into health care services with the acquisition of U.S. Oncology, an integrated cancer care company, whose expertise it could leverage in offerings catered to other physician specialties. Wi...Starting at €8.20
-
Brasil Foods
Bell, David E.; Kindred, NatalieCase HBS-512013-EStrategyIn mid-2011, the management of Brasil Foods, a leading Brazilian branded foods producer and protein exporter, is evaluating strategies for international and domestic growth. The team has just received approval from Brazil's antitrust authorities to complete the merger of Perdigao and Sadia, the two massive food producers that had combined to form Brasil Foods in 2009. Now, the team is free to focus on their ambitious plan to double revenues by 20...Starting at €8.20